JP2016515528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515528A5 JP2016515528A5 JP2016503239A JP2016503239A JP2016515528A5 JP 2016515528 A5 JP2016515528 A5 JP 2016515528A5 JP 2016503239 A JP2016503239 A JP 2016503239A JP 2016503239 A JP2016503239 A JP 2016503239A JP 2016515528 A5 JP2016515528 A5 JP 2016515528A5
- Authority
- JP
- Japan
- Prior art keywords
- mannitol
- cyclobenzaprine hcl
- item
- pharmaceutical composition
- eutectic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000594 mannitol Substances 0.000 claims description 78
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 74
- 229930195725 Mannitol Natural products 0.000 claims description 74
- 235000010355 mannitol Nutrition 0.000 claims description 74
- 229960003572 cyclobenzaprine Drugs 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 230000005496 eutectics Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 239000002610 basifying agent Substances 0.000 claims description 17
- 239000000155 melt Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 229940038773 trisodium citrate Drugs 0.000 claims description 2
- -1 trisodium citrate anhydride Chemical class 0.000 claims description 2
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims 22
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- FJXYMVBFBYAWDR-UHFFFAOYSA-N tributyl(prop-1-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C\C FJXYMVBFBYAWDR-UHFFFAOYSA-N 0.000 description 33
- 229960000836 amitriptyline Drugs 0.000 description 32
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 32
- 238000002156 mixing Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792757P | 2013-03-15 | 2013-03-15 | |
| US61/792,757 | 2013-03-15 | ||
| PCT/US2014/029872 WO2014145156A2 (en) | 2013-03-15 | 2014-03-14 | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027899A Division JP2018087231A (ja) | 2013-03-15 | 2018-02-20 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515528A JP2016515528A (ja) | 2016-05-30 |
| JP2016515528A5 true JP2016515528A5 (enExample) | 2017-04-20 |
| JP6310542B2 JP6310542B2 (ja) | 2018-04-11 |
Family
ID=51538423
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503239A Active JP6310542B2 (ja) | 2013-03-15 | 2014-03-14 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2018027899A Withdrawn JP2018087231A (ja) | 2013-03-15 | 2018-02-20 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2019151766A Withdrawn JP2019196407A (ja) | 2013-03-15 | 2019-08-22 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2021105582A Withdrawn JP2021143208A (ja) | 2013-03-15 | 2021-06-25 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2023188486A Pending JP2023181495A (ja) | 2013-03-15 | 2023-11-02 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027899A Withdrawn JP2018087231A (ja) | 2013-03-15 | 2018-02-20 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2019151766A Withdrawn JP2019196407A (ja) | 2013-03-15 | 2019-08-22 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2021105582A Withdrawn JP2021143208A (ja) | 2013-03-15 | 2021-06-25 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
| JP2023188486A Pending JP2023181495A (ja) | 2013-03-15 | 2023-11-02 | シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (11) | US9636408B2 (enExample) |
| EP (2) | EP3650081B1 (enExample) |
| JP (5) | JP6310542B2 (enExample) |
| CN (2) | CN105142730B (enExample) |
| AU (1) | AU2014233277B2 (enExample) |
| BR (1) | BR112015022095B1 (enExample) |
| CA (2) | CA2904812C (enExample) |
| CY (1) | CY1122740T1 (enExample) |
| DK (2) | DK2968992T3 (enExample) |
| ES (2) | ES2769879T3 (enExample) |
| FI (1) | FI3650081T3 (enExample) |
| HR (2) | HRP20200055T1 (enExample) |
| HU (2) | HUE047547T2 (enExample) |
| IL (1) | IL241353B (enExample) |
| LT (2) | LT3650081T (enExample) |
| MX (2) | MX388137B (enExample) |
| MY (1) | MY196014A (enExample) |
| NZ (2) | NZ631152A (enExample) |
| PL (2) | PL2968992T3 (enExample) |
| PT (2) | PT3650081T (enExample) |
| RS (2) | RS60015B1 (enExample) |
| SA (1) | SA515361124B1 (enExample) |
| SG (2) | SG11201507124XA (enExample) |
| SI (2) | SI2968992T1 (enExample) |
| SM (2) | SMT202400324T1 (enExample) |
| TW (2) | TWI661825B (enExample) |
| WO (1) | WO2014145156A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8483821B2 (en) | 2009-07-27 | 2013-07-09 | Cardiac Pacemakers, Inc. | Blood volume redistribution therapy for heart failure |
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| MX382516B (es) * | 2012-06-15 | 2025-03-13 | Tonix Pharmaceuticals Inc | Composiciones y metodos para absorcion transmucosa. |
| NZ631152A (en) | 2013-03-15 | 2017-05-26 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| MX383378B (es) | 2014-02-05 | 2025-03-13 | Merck Sharp & Dohme Llc | Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina. |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US10357465B2 (en) * | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| JP2021505629A (ja) * | 2017-12-11 | 2021-02-18 | トニックス ファーマ ホールディングス リミテッド | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2021002012A (es) * | 2018-08-20 | 2021-04-28 | Tonix Pharma Holdings Ltd | Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico. |
| NL2023661B1 (en) * | 2019-08-19 | 2021-04-21 | Seranovo Holding B V | Pharmaceutical Eutectic Salt Formulation |
| JP7088153B2 (ja) * | 2019-09-19 | 2022-06-21 | カシオ計算機株式会社 | Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム |
| WO2021207561A1 (en) | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| EP4247370A1 (en) * | 2020-11-20 | 2023-09-27 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
| JP2023554692A (ja) | 2020-12-07 | 2023-12-28 | トニックス ファーマシューティカルズ ホールディング コーポレイション | 線維筋痛症のためのシクロベンザプリン処置 |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| CN113116843A (zh) * | 2021-05-11 | 2021-07-16 | 福建海西新药创制有限公司 | 一种含有缬沙坦的药物组合物及其制备方法 |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| WO2023059728A1 (en) | 2021-10-06 | 2023-04-13 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| CN120379655A (zh) | 2022-06-21 | 2025-07-25 | 通尼克斯医药控股公司 | (sars)-cov-2感染的急性后后遗症(pasc)的环苯扎林治疗 |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
| CN120059783B (zh) * | 2025-04-24 | 2025-07-04 | 太原理工大学 | 一种低共熔溶剂循环萃取促进沥青快速氧化的方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| JP2551754B2 (ja) * | 1986-04-17 | 1996-11-06 | 内橋エステック 株式会社 | ペレツト型温度ヒユ−ズ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| FR2635461B1 (fr) | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1994018954A1 (en) | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE4439858A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| CA2331542A1 (en) | 1998-05-14 | 1999-11-18 | Alza Corporation | Antidepressant therapy |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| ES2192156B1 (es) | 1999-08-13 | 2005-02-16 | Vela Pharmaceuticals, Inc. | Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. |
| US6358944B1 (en) | 1999-08-13 | 2002-03-19 | Vela Pharmaceuticals, Inc. | Methods and compositions for treating generalized anxiety disorder |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| DK1441708T3 (da) | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| MXPA05004381A (es) | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US20050059656A1 (en) | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
| KR101170840B1 (ko) | 2003-05-29 | 2012-08-03 | 샤이어 엘엘씨 | 남용 방지성 암페타민 화합물 |
| EP1685115A1 (en) | 2003-11-03 | 2006-08-02 | Warner-Lambert Company LLC | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| EP1727520A2 (en) * | 2003-12-09 | 2006-12-06 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| KR20070030178A (ko) | 2004-02-17 | 2007-03-15 | 트랜스오랄 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법 |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| TWI377913B (en) | 2005-01-24 | 2012-12-01 | Food Science Co Ltd B | Eutectic crystalline sugar alcohol and manufacturing method thereof |
| US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20080146672A1 (en) * | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| EP2514417A3 (en) | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| EP2170064A4 (en) | 2007-06-22 | 2010-08-04 | Merck Sharp & Dohme | 6,5-pyrrolopiperidine tachykinin receptor antagonists |
| NZ583193A (en) | 2007-07-23 | 2012-05-25 | Biotie Therapies Inc | Treatment of post-traumatic stress disorder with nepicastat |
| US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| US9254268B2 (en) | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| JP5737949B2 (ja) | 2008-02-08 | 2015-06-17 | キューピーエス リミテッド ライアビリティ カンパニー | 薬物制御送達用の非ポリマー組成物 |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
| US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| US8871263B2 (en) * | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| WO2012050594A1 (en) | 2010-09-01 | 2012-04-19 | Tonix Pharmaceuticals, Inc. | Treatment for cocaine addiction |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| ITMI20110558A1 (it) | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| US20130035362A1 (en) | 2011-08-04 | 2013-02-07 | Omeros Corporation | Stable Anti-inflammatory Solutions for Injection |
| MX382516B (es) | 2012-06-15 | 2025-03-13 | Tonix Pharmaceuticals Inc | Composiciones y metodos para absorcion transmucosa. |
| NZ631152A (en) * | 2013-03-15 | 2017-05-26 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| US10357465B2 (en) | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| MX2021002012A (es) | 2018-08-20 | 2021-04-28 | Tonix Pharma Holdings Ltd | Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico. |
-
2014
- 2014-03-14 NZ NZ631152A patent/NZ631152A/en unknown
- 2014-03-14 MY MYPI2015703142A patent/MY196014A/en unknown
- 2014-03-14 MX MX2019014200A patent/MX388137B/es unknown
- 2014-03-14 HU HUE14762323A patent/HUE047547T2/hu unknown
- 2014-03-14 FI FIEP19214535.7T patent/FI3650081T3/fi active
- 2014-03-14 PT PT192145357T patent/PT3650081T/pt unknown
- 2014-03-14 SG SG11201507124XA patent/SG11201507124XA/en unknown
- 2014-03-14 NZ NZ747040A patent/NZ747040A/en unknown
- 2014-03-14 TW TW103109816A patent/TWI661825B/zh active
- 2014-03-14 SI SI201431487T patent/SI2968992T1/sl unknown
- 2014-03-14 HR HRP20200055TT patent/HRP20200055T1/hr unknown
- 2014-03-14 LT LTEP19214535.7T patent/LT3650081T/lt unknown
- 2014-03-14 PL PL14762323T patent/PL2968992T3/pl unknown
- 2014-03-14 EP EP19214535.7A patent/EP3650081B1/en active Active
- 2014-03-14 DK DK14762323.5T patent/DK2968992T3/da active
- 2014-03-14 AU AU2014233277A patent/AU2014233277B2/en active Active
- 2014-03-14 HU HUE19214535A patent/HUE066883T2/hu unknown
- 2014-03-14 SI SI201432074T patent/SI3650081T1/sl unknown
- 2014-03-14 JP JP2016503239A patent/JP6310542B2/ja active Active
- 2014-03-14 DK DK19214535.7T patent/DK3650081T3/da active
- 2014-03-14 SM SM20240324T patent/SMT202400324T1/it unknown
- 2014-03-14 RS RS20200094A patent/RS60015B1/sr unknown
- 2014-03-14 PL PL19214535.7T patent/PL3650081T3/pl unknown
- 2014-03-14 LT LTEP14762323.5T patent/LT2968992T/lt unknown
- 2014-03-14 ES ES14762323T patent/ES2769879T3/es active Active
- 2014-03-14 CA CA2904812A patent/CA2904812C/en active Active
- 2014-03-14 RS RS20240532A patent/RS65500B1/sr unknown
- 2014-03-14 SG SG10201707528WA patent/SG10201707528WA/en unknown
- 2014-03-14 SM SM20200045T patent/SMT202000045T1/it unknown
- 2014-03-14 US US14/214,433 patent/US9636408B2/en active Active
- 2014-03-14 PT PT147623235T patent/PT2968992T/pt unknown
- 2014-03-14 HR HRP20240648TT patent/HRP20240648T1/hr unknown
- 2014-03-14 CN CN201480024011.1A patent/CN105142730B/zh active Active
- 2014-03-14 US US14/776,624 patent/US10117936B2/en active Active
- 2014-03-14 TW TW108114946A patent/TWI740136B/zh active
- 2014-03-14 EP EP14762323.5A patent/EP2968992B8/en active Active
- 2014-03-14 MX MX2015012622A patent/MX370021B/es active IP Right Grant
- 2014-03-14 CA CA3119755A patent/CA3119755C/en active Active
- 2014-03-14 WO PCT/US2014/029872 patent/WO2014145156A2/en not_active Ceased
- 2014-03-14 CN CN201910263541.6A patent/CN110152005B/zh active Active
- 2014-03-14 ES ES19214535T patent/ES2982441T3/es active Active
- 2014-03-14 BR BR112015022095-9A patent/BR112015022095B1/pt active IP Right Grant
-
2015
- 2015-09-09 IL IL24135315A patent/IL241353B/en active IP Right Grant
- 2015-09-14 SA SA515361124A patent/SA515361124B1/ar unknown
-
2017
- 2017-03-15 US US15/459,093 patent/US9956188B2/en active Active
-
2018
- 2018-02-20 JP JP2018027899A patent/JP2018087231A/ja not_active Withdrawn
- 2018-03-30 US US15/941,484 patent/US10322094B2/en active Active
- 2018-09-24 US US16/140,090 patent/US10864175B2/en active Active
- 2018-09-24 US US16/140,105 patent/US10864176B2/en active Active
-
2019
- 2019-06-03 US US16/429,852 patent/US10736859B2/en active Active
- 2019-08-22 JP JP2019151766A patent/JP2019196407A/ja not_active Withdrawn
-
2020
- 2020-02-05 CY CY20201100104T patent/CY1122740T1/el unknown
- 2020-10-28 US US17/082,949 patent/US11839594B2/en active Active
- 2020-12-14 US US17/121,547 patent/US11737991B2/en active Active
-
2021
- 2021-06-25 JP JP2021105582A patent/JP2021143208A/ja not_active Withdrawn
-
2023
- 2023-10-31 US US18/385,468 patent/US20240315988A1/en not_active Abandoned
- 2023-11-02 JP JP2023188486A patent/JP2023181495A/ja active Pending
-
2025
- 2025-06-06 US US19/230,858 patent/US20250360093A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515528A5 (enExample) | ||
| ES2923214T3 (es) | Composición farmacéutica que comprende mesilato de lenvatinib | |
| NO20050688L (no) | Fast stoff farmasoytiske preparater inneholdende telmisartan | |
| JP5859664B2 (ja) | 薬物の味がマスクされた経口用薬学組成物及びその製造方法 | |
| JP2015535289A5 (enExample) | ||
| AU2013219296C1 (en) | Oral pharmaceutical composition | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| JP6347891B2 (ja) | 液状医薬組成物 | |
| JP6126456B2 (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
| AR105203A1 (es) | Formulación oral sólida que contiene irinotecán y método de preparación de la misma | |
| JP2018090490A (ja) | ミラベグロン含有医薬組成物 | |
| JP2008531614A5 (enExample) | ||
| AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
| ES2922903T3 (es) | Composición farmacéutica que comprende sales de lenvatinib | |
| JP2012529431A (ja) | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 | |
| JP2017141299A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
| ES3049195T3 (en) | Pharmaceutical capsule composition of rivaroxaban | |
| JP2011525901A (ja) | ロスバスタチンカルシウム含有医薬組成物 | |
| JPS58109412A (ja) | ニフエジピン固形製剤 | |
| JP6371920B2 (ja) | 新規薬学組成物 | |
| ITMI20010428A1 (it) | Composizioni ad uso inalatorio a base di formoterolo | |
| HRP20130093T1 (hr) | Formulacije 14-epi-analoga vitamina d | |
| JP6485120B2 (ja) | 固形製剤 | |
| US20150025148A1 (en) | Alditol free, storage stable thyroid hormone active drug formulations and methods for their production | |
| HRP20201436T1 (hr) | Makrogoli za davanje na sluznicu i njihove terapeutske primjene |